A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation—KRAS circulating tumor DNA (ctDNA)—strongly indicates a higher risk of cancer spread and worse ...
Mar 19, 2025
0
0
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy ...
Mar 14, 2025
0
41
Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolic "switch" to help it spread, revealing a potential new treatment strategy for this highly aggressive ...
Mar 14, 2025
0
42
For cancers of organs like the liver, the long-term impact of our diet has been well studied—so much so that we have guidance about red meat, wine and other delicacies.
Mar 13, 2025
0
15
Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic cancer respond to immunotherapies. The findings, which were recently published in the journal Cancer ...
Mar 12, 2025
0
0
Pancreatic cancer is one of the deadliest cancers worldwide, with a five-year survival rate of 13%. This poor prognosis stems from both late detection and the cancer's notorious capacity to adapt and resist therapy.
Mar 12, 2025
0
21
Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and their collaborators demonstrated ...
Mar 10, 2025
0
26
The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma cases, according to Hao Xie, MD, PhD, a medical oncologist at Mayo Clinic Comprehensive Cancer Center.
Mar 3, 2025
0
0
Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8+ T cells in patients with pancreatic ductal adenocarcinoma (PDAC), potentially delaying disease ...
Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet promising study from Memorial Sloan Kettering Cancer Center.
Feb 21, 2025
0
1
Pancreatic cancer refers to a malignant neoplasm originating from transformed cells arising in tissues forming the pancreas. The most common type of pancreatic cancer, accounting for 95% of these tumors, is adenocarcinoma (tumors exhibiting glandular architecture on light microscopy) arising within the exocrine component of the pancreas. A minority arise from islet cells, and are classified as neuroendocrine tumors. The symptoms that lead to diagnosis depend on the location, the size, and the tissue type of the tumor. They may include abdominal pain and jaundice (if the tumor compresses the bile duct).
Pancreatic cancer is the fourth most common cause of cancer death across the globe. Pancreatic cancer often has a poor prognosis: for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, respectively; for local disease the 5-year survival is approximately 20% while the median survival for locally advanced and for metastatic disease, which collectively represent over 80% of individuals, is about 10 and 6 months respectively.
This text uses material from Wikipedia licensed under CC BY-SA
